Less than a decade on from genetic studies indicating the potential of PCSK9 as a target to affect cholesterol metabolism, two PCSK9 inhibitors are moving into late-stage development.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov 11, 817–819 (2012). https://doi.org/10.1038/nrd3879
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3879
This article is cited by
-
Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network
Scientific Reports (2018)
-
Redefining the role of biomarkers in heart failure trials: expert consensus document
Heart Failure Reviews (2017)
-
Validating therapeutic targets through human genetics
Nature Reviews Drug Discovery (2013)
